Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 32.5 CNY -5.93% Market Closed
Market Cap: 5.7B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Net Margin
Chengdu Easton Biopharmaceuticals Co Ltd

20.8%
Current
21%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.8%
=
Net Income
240.6m
/
Revenue
1.2B

Net Margin Across Competitors

Country CN
Market Cap 5.7B CNY
Net Margin
21%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 710.5B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.5B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 202.7B CHF
Net Margin
20%
Country CH
Market Cap 183.3B CHF
Net Margin
35%
Country UK
Market Cap 162.4B GBP
Net Margin
13%
Country IE
Market Cap 146B USD
Net Margin
-126%
No Stocks Found

Chengdu Easton Biopharmaceuticals Co Ltd
Glance View

Market Cap
5.7B CNY
Industry
Pharmaceuticals

Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Intrinsic Value
49.88 CNY
Undervaluation 35%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
20.8%
=
Net Income
240.6m
/
Revenue
1.2B
What is the Net Margin of Chengdu Easton Biopharmaceuticals Co Ltd?

Based on Chengdu Easton Biopharmaceuticals Co Ltd's most recent financial statements, the company has Net Margin of 20.8%.